Structural and Pharmacological Evaluation of a Novel Non-nucleoside Reverse Transcriptase Inhibitor as a Promising Long Acting Nanoformulation for Treating HIV

Ítems similars

• Structural and Preclinical Studies of Computationally Designed Non-Nucleoside Reverse Transcriptase Inhibitors for Treating HIV infection
  per: Kudalkar, Shalley N., et al.
  Publicat: (2017)
• From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection
  per: Kudalkar, Shalley N., et al.
  Publicat: (2018)
• Reply to Pandey et al.: Understanding the efficacy of a potential antiretroviral drug candidate in humanized mouse model of HIV infection
  per: Kudalkar, Shalley N., et al.
  Publicat: (2018)
• Pharmacology of current and promising nucleosides for the treatment of human immunodeficiency viruses
  per: Schinazi, Raymond F., et al.
  Publicat: (2006)
• Structural insights into the recognition of nucleoside reverse transcriptase inhibitors by HIV‐1 reverse transcriptase: First crystal structures with reverse transcriptase and the active triphosphate forms of lamivudine and emtricitabine
  per: Bertoletti, Nicole, et al.
  Publicat: (2019)